Published in Vaccine Weekly, January 20th, 2010
OncoVEXGM-CSF is currently in a pivotal Phase 3 study in melanoma (the OPTiM trial), being conducted under a Special Protocol Assessment (SPA), and preparations for an additional Phase 3 trial in head and neck cancer, also approved by the FDA under the SPA procedure, are underway.
"Tim is a seasoned executive in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly